Education
About Us
Working with TipRanks
Follow Us
Luye Pharma Group Ltd. (LYPHF)
OTHER OTC:LYPHF
Total Valuation
Luye Pharma Group has a market cap or net worth of $867.25M. The enterprise value is $12.88B.
Market Cap$867.25M
Enterprise Value$12.88B
Share Statistics
Luye Pharma Group has 3.76B shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding3.76B
Owened by Insiders
Owened by Instutions
Financial Efficiency
Luye Pharma Group’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee$1,515,673.863
Profits Per Employee$183,755.827
Employee Count5,234
Asset Turnover―
Inventory Turnover―
Valuation Ratios
The current PE Ratio of Luye Pharma Group is ―. Luye Pharma Group’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value―
Price to FCF―
Price to Operating Cash Flow―
PEG Ratio―
Income Statement
In the last 12 months, Luye Pharma Group had revenue of $7.93B and earned $961.78M in profits. Earnings per share was $0.25.
Revenue$7.93B
Gross Profit$5.47B
Operating Income$1.68B
Pretax Income$1.24B
Net Income$961.78M
EBITDA2.48B
Earnings Per Share (EPS)0.25
Cash Flow
In the last 12 months, operating cash flow was $964.24M and capital expenditures -$948.98M, giving a free cash flow of $15.26M billion.
Operating Cash Flow$964.24M
Free Cash Flow$15.26M
Free Cash Flow per Share<$0.01
Dividends & Yields
Luye Pharma Group pays an annual dividend of <$0.01, resulting in a dividend yield of
Dividend Per Share<$0.01
Dividend Yield
Payout Ratio
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.49
52-Week Price Change-20.59%
50-Day Moving Average0.29
200-Day Moving Average0.33
Relative Strength Index (RSI)31.16
Average Volume (3m)127.00
Important Dates
Luye Pharma Group upcoming earnings date is Aug 27, 2025, TBA.
Last Earnings DateMar 28, 2025
Next Earnings DateAug 27, 2025
Ex-Dividend DateJun 29, 2020
Financial Position
Luye Pharma Group as a current ratio of ―, with Debt / Equity ratio of ―
Current Ratio―
Quick Ratio―
Debt to Market Cap―
Net Debt to EBITDA―
Interest Coverage Ratio―
Taxes
In the past 12 months, Luye Pharma Group has paid $207.88M in taxes.
Income Tax$207.88M
Effective Tax Rate―
Enterprise Valuation
Luye Pharma Group EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
Luye Pharma Group has $6.48B in cash and marketable securities with $9.45B in debt, giving a net cash position of $2.97B billion.
Cash & Marketable Securities$6.48B
Total Debt$9.45B
Net Cash$2.97B
Net Cash Per Share$0.79
Tangible Book Value Per Share―
Margins
Gross margin is ―, with operating margin of ―, and net profit margin of ―.
Gross Margin―
Operating Margin―
Pretax Margin―
Net Profit Margin―
EBITDA Margin―
EBIT Margin―
Analyst Forecast
The average price target for Luye Pharma Group is $0.38, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$0.38
Price Target Upside40.74%
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast
EPS Growth Forecast